NEW YORK (360Dx) – With the recent launch of its mass spectrometry RenataDx Screening System, Waters is looking to reinforce its position in the newborn screening market and serve growing demand for newborn screening in the developing world.

The company introduced the system last month. Combining Waters' Xevo TDQ IVD mass spec, ACQUITY UPLC I-Class IVD Binary Solvent Manager, and the 3777C IVD Sample Manager along with the company's MassLynx and IonLynx software, the platform uses flow-injection tandem mass spec to enable high-throughput analysis of dried blood spots.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.